Drug Trial Radar · NCT01386294
Safety and Effectiveness of Tenofovir Gel in the Prevention of Human Immunodeficiency Virus (HIV-1) Infection in Women and the Effects of Tenofovir Gel on the Incidence of Herpes Simplex Virus (HSV-2) Infection
Last checked: Nov 19, 2026Latest source record: Apr 17, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,059
Actual
Start
Oct 2011
Primary completion
Aug 2014
Study completion Aug 2014
Sponsor
- Lead sponsor
- CONRADAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Follow-on African Consortium for Tenofovir Studies (FACTS); United States Agency for International Development (USAID)
- First posted
- Jul 1, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- Female only, from 18 years, up to 40 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of the study is to assess the safety and effectiveness of intravaginal 1% tenofovir gel in preventing Human Immunodeficiency Virus (HIV-1) infection and Herpes Simplex Virus (HSV-2) infection in sexually active women.
Conditions
- HIV Prevention
Interventions
Tenofovir gelDrug
Tenofovir gel is a clear, transparent, viscous gel at concentrations of 1% formulated in purified water with edentate disodium, citric acid, glycerin, methylparaben, propylparaben, HEC, and pH adjusted to 4-5. Tenofovir gel will be supplies in a 4 ml single use applicator containing approximately 4 grams of gel, equivalent to approximately 40mg of tenofovir.
Universal placebo gelDrug
The placebo gel is an inert gel containing HEC as the gelling agent, purified water, sodium chloride, sorbic acid and sodium hydroxide. Each applicator contains approximately 4ml of placebo gel
Primary outcomes
What the sponsor says the trial is designed to measure.
- EffectivenessTime frame: 30 months
- SafetyTime frame: 30 months
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
Desmond Tutu HIV Centre / University of Cape Town
Cape Town, South Africa
Perinatal HIV Research Unit / University of the Witwatersrand
Diepkloof, South Africa
Wits Reproductive Health and HIV Institute / University of the Witwatersrand
Hillbrow, South Africa
Qhakaza Mbokodo Research Clinic
Ladysmith, South Africa
Medunsa Clinical Research Unit / Ga-Ra
Pretoria, South Africa
The Aurum Institute (Rustenburg)
Rustenburg, South Africa
Setshaba Research Centre
Soshanguve, South Africa
The Aurum Institute, Tembisa Hospital
Tembisa, South Africa
MatCH Edendale Research Center
Pietermaritzburg, KwaZulu-Natal, South Africa
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.